Table 1.
Population characteristics at baseline
| Demographic Characteristics | Olmesartan | Other ARBs | ACE‐i |
|---|---|---|---|
| Patients (n, %) | 25,591 (5.5) | 104,901 (22.5) | 334,951 (72.0) |
| Age (mean, SD) | 63.0 (14.0) | 65.0 (14.4) | 62.4 (14.7) |
| Age (n, %) | |||
| Missing | 17 (0.1) | 143 (0.1) | 862 (0.3) |
| <50 | 4,757 (18.6) | 16,803 (16.1) | 68,349 (20.4) |
| 50–60 | 5,916 (23.1) | 20,826 (19.9) | 77,950 (23.3) |
| 60–70 | 5,923 (23.1) | 22,839 (21.8) | 70,655 (21.1) |
| 70–80 | 5,575 (21.8) | 25,626 (24.4) | 71,065 (21.2) |
| ≥80 | 3,403 (13.3) | 18,664 (17.8) | 46,070 (13.8) |
| Female (n, %) | 12,728 (49.7) | 54,597 (52.1) | 154,923 (46.3) |
| Comorbiditiesa | 3,789 (14.8) | 21,982 (21.0) | 87,636 (26.1) |
| Diabetes (n, %) | 2,301 (9.0) | 12,190 (11.6) | 46,899 (14.0) |
| Transplantation (n, %) | 35 (0.1) | 285 (0.3) | 959 (0.3) |
| Malignant neoplasms (n, %) | 1,021 (4.0) | 6,931 (6.6) | 32,300 (9.6) |
| Renal failure (n, %) | 432 (1.7) | 2,576 (2.5) | 7,478 (2.2) |
ACE‐i indicates angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker.
a
The total number of comorbidities could exceed the total number of patients with at least 1 comorbidity because 1 patient could have more than 1 comorbidity of interest.